IMTX

Immatics
IMTX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$660.02M
EV
$92.17M
Shares Outstanding
121.75M
Beta
0.82

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$14.33
P/E 2025E
-
P/Revenue 2025E
9.63x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Immatics N.V.

gainify
IMTX

Immatics N.V.

IMTX

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on trea...

Sector

Healthcare

Industry

Biotechnology

CEO

Singh, Harpreet

Employees

646

IPO Date

2018-12-12

Headquarters

Paul-Ehrlich-Strasse 15, Tübingen, Baden-Württemberg, 72076, Germany

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.